Skip to content
TrackPodcasts
healthMay 12, 202520:57pending

Zepbound versus Wegovy

Docs Who Lift

About this episode

  • Tirzepatide is more effective for weight loss than semaglutide.
  • Cost-effectiveness is crucial in prescribing weight loss medications.
  • Patients with severe obesity should receive more expensive medications for better outcomes.
  • Both medications show significant benefits for obesity-related conditions.
  • Long-term studies indicate sustained weight loss with both drugs.
  • Gender differences affect weight loss outcomes with these medications.
  • Safety profiles show tirzepatide may be better tolerated than semaglutide.
  • The need for affordable drug pricing is emphasized.
  • Clinical benefits extend beyond weight loss to include metabolic health.
  • Future studies are needed to confirm cardiovascular benefits of tirzepatide.

Click here to see the study

Click here to join Dr. Spencer's new online clinic


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Get every episode summarized

Each time Docs Who Lift publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Zepbound versus Wegovy

Docs Who Lift

0:00
20:57

More episodes

More from Docs Who Lift

View all episodes →